AKINETON
Clinical safety rating: caution
Comprehensive clinical and safety monograph for AKINETON (AKINETON).
Akineton (biperiden) is an anticholinergic agent that blocks central muscarinic acetylcholine receptors, thereby reducing cholinergic overactivity in the basal ganglia and improving symptoms of Parkinsonism.
| Metabolism | Biperiden is extensively metabolized in the liver via hydroxylation and glucuronidation. The major metabolic pathway involves hydroxylation of the piperidine ring. |
| Excretion | Primarily renal excretion of unchanged drug and metabolites (approximately 60-70% as unchanged biperiden). Minor biliary/fecal elimination (<10%). |
| Half-life | Terminal elimination half-life ranges from 18 to 24 hours in young adults; prolonged to 24-38 hours in elderly patients. Steady-state achieved within 4-6 days. |
| Protein binding | Approximately 60% bound to plasma proteins, primarily albumin. |
| Volume of Distribution | 5-8 L/kg, indicating extensive tissue distribution and high CNS penetration (brain-to-plasma ratio approximately 10:1). |
| Bioavailability | Oral: 30-50% due to first-pass metabolism; intramuscular: near 100%. |
| Onset of Action | Oral: 1-2 hours; intramuscular: 10-15 minutes; intravenous: 5-10 minutes. |
| Duration of Action | Oral: 6-12 hours depending on dose; parenteral: 2-4 hours. Clinical effect may persist beyond plasma half-life due to central dopamine receptor binding. |
2 mg orally 2-4 times daily, titrated up to 6-20 mg/day in divided doses; immediate-release tablets only.
| Dosage form | INJECTABLE |
| Renal impairment | No specific guidelines; use caution with GFR <10 mL/min due to potential accumulation. |
| Liver impairment | Contraindicated in severe hepatic impairment (Child-Pugh C). In mild-to-moderate impairment, reduce dose by 50%. |
| Pediatric use | 0.04-0.08 mg/kg/day orally in 2-4 divided doses; max 0.2 mg/kg/day. Not recommended in children <3 years. |
| Geriatric use | Initial dose 1 mg orally 1-2 times daily; increase slowly. Increased risk of anticholinergic side effects; avoid in patients with dementia. |
| 1st trimester | Consult provider |
| 2nd trimester | Consult provider |
| 3rd trimester | Consult provider |
Clinical note
Comprehensive clinical and safety monograph for AKINETON (AKINETON).
| Breastfeeding | Biperiden is excreted into breast milk in small amounts; M/P ratio is unknown. Due to the potential for anticholinergic effects in the nursing infant (e.g., constipation, drowsiness), caution is advised. Manufacturer recommends discontinuing breastfeeding or avoiding the drug. |
| Teratogenic Risk | Akineton (biperiden) is classified as FDA Pregnancy Category C. Animal studies have shown embryotoxic effects at high doses, but no adequate human studies exist. First trimester: potential risk of congenital anomalies cannot be excluded. Second and third trimesters: may cause anticholinergic effects in the neonate (e.g., ileus, feeding difficulties). Use only if clearly needed. |
■ FDA Black Box Warning
None
| Serious Effects |
["Hypersensitivity to biperiden","Narrow-angle glaucoma","Obstruction of the gastrointestinal or genitourinary tract","Paralytic ileus","Mega colon","Severe ulcerative colitis","Myasthenia gravis"]
| Precautions | ["May impair mental or physical abilities (e.g., driving).","Use with caution in patients with glaucoma, prostatic hypertrophy, or urinary retention.","Elderly patients are more sensitive to anticholinergic effects.","May cause hyperthermia in hot environments.","May worsen tardive dyskinesia or other movement disorders."] |
| Food/Dietary | No significant food interactions reported. Avoid alcohol due to additive CNS depression. Maintain adequate fluid intake to prevent constipation. |
Loading safety data…
| Fetal Monitoring | Monitor maternal vital signs, anticholinergic side effects (dry mouth, blurred vision, urinary retention). In neonate: observe for anticholinergic symptoms (e.g., abdominal distension, feeding intolerance). |
| Fertility Effects | No specific human data on fertility. Animal studies suggest possible impairment of fertility at high doses. Anticholinergic effects may theoretically affect reproductive function via altered autonomic regulation. |
| Clinical Pearls | AKINETON (biperiden) is an anticholinergic agent used for Parkinsonism and drug-induced extrapyramidal symptoms. Monitor for anticholinergic side effects like confusion, urinary retention, and constipation, especially in elderly. Use with caution in patients with glaucoma, prostatic hypertrophy, or tachycardia. Abrupt withdrawal may precipitate parkinsonian crisis. |
| Patient Advice | Take exactly as prescribed; do not stop suddenly without consulting your doctor. · Avoid alcohol and CNS depressants as they may increase drowsiness. · Report symptoms like confusion, difficulty urinating, or vision changes immediately. · May cause dry mouth; use sugar-free gum or candy for relief. · Avoid overheating during exercise or hot weather; may decrease sweating. · Not recommended for use in children under 3 years or tardive dyskinesia. |